New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
Statin Prescribing Patterns in Patient-Centered Medical Home Patients With NAFLD
Impact of Direct-Acting Antiviral Use for Chronic Hepatitis C on Health Care Costs in Medicaid: Economic Model Update
Pathological Neutrophil Migration in Cirrhosis Linked to Increased Risk of AEs
Dr Nancy Reau on How to Educate Providers on Liver Disease Guidelines
Dr Nancy Reau Covers Alcohol Use Disorder Interventions to Prevent Alcoholic Hepatitis
Dr Nancy Reau: COVID-19, Drinking Patterns, Lifestyle Factors Causing Increased Alcoholic Hepatitis Hospitalizations
Provider Knowledge on Liver Disease Guidelines Varies, Dr Nancy Reau Says
Dr Karen Watkins Details the Obstacles Impeding Effective Treatment for Patients With NASH
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists
Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition
Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape
Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches
MA Beneficiaries May Be at Disadvantage for Complex Cancer Surgeries